Publications by authors named "Y Shibamoto"
Article Synopsis
- The study aimed to identify dosimetric factors that predict the risk of brain necrosis (BN) in patients undergoing fractionated stereotactic radiotherapy (SRT) for brain metastases.
- Researchers used multivariate logistic models to analyze data from patients who received various SRT doses, calculating the volume of normal brain exposed to specific biological doses (VxxEQD2).
- Results indicated that larger volumes of the brain receiving higher doses (V55EQD2 and V60EQD2) were associated with increased chances of developing symptomatic BN, emphasizing the need for careful planning to minimize exposure.
Background And Purpose: Interfractional geometrical and anatomical variations impact the accuracy of proton therapy for pancreatic cancer. This study investigated field-in-field (FIF) and simultaneous integrated boost (SIB) concepts for scanned proton therapy treatment with different beam configurations.
Materials And Methods: Robustly optimized treatment plans for fifteen patients were generated using FIF and SIB techniques with two, three, and four beams.
This study investigated the appropriate dose prescription method in static multi-beam stereotactic body radiotherapy for lung tumors. Static multi-beam stereotactic body radiotherapy is a mainstream treatment in Japan. Based on the hypothesis that dose prescription to lower isodose lines may improve planning target volume dose coverage and decrease doses to organs at risk, we investigated changes in dose-volume histograms with prescription to various isodose lines for planning target volume in static multi-beam stereotactic body radiotherapy.
View Article and Find Full Text PDFIntroduction: Radiation therapy (RT) for choroidal metastasis (CM) aims to preserve vision and achieve local control (LC), thereby maintaining quality of life. The present study reports the clinical outcomes of RT for CM and reviews the literature.
Methods: We retrospectively collected data on 11 patients with CM; their primary tumors were breast cancer (n=3), lung cancer (n=3), leukemia (n=2), lymphoma (n=2), and gastric cancer (n=1).
Background/aim: The 8 edition of the American Joint Committee on Cancer staging system classifies oropharyngeal cancer (OPC) by the expression of p16. The discrepancy observed in this system between pathological and clinical N-stages in p16-positive OPC has provoked controversy. Therefore, this study investigated prognostic factors not included in the new staging system for p16-positive OPC patients.
View Article and Find Full Text PDF